MX2022015326A - Receptores de antigeno quimerico anti-cd171. - Google Patents

Receptores de antigeno quimerico anti-cd171.

Info

Publication number
MX2022015326A
MX2022015326A MX2022015326A MX2022015326A MX2022015326A MX 2022015326 A MX2022015326 A MX 2022015326A MX 2022015326 A MX2022015326 A MX 2022015326A MX 2022015326 A MX2022015326 A MX 2022015326A MX 2022015326 A MX2022015326 A MX 2022015326A
Authority
MX
Mexico
Prior art keywords
cars
chimeric antigen
antigen receptors
cells containing
relate
Prior art date
Application number
MX2022015326A
Other languages
English (en)
Inventor
Michael C Jensen
Adam Johnson
Original Assignee
Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital Dba Seattle Childrens Res Inst filed Critical Seattle Childrens Hospital Dba Seattle Childrens Res Inst
Publication of MX2022015326A publication Critical patent/MX2022015326A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

Las modalidades de los métodos y composiciones que se proporcionan en este documento se refieren a receptores de antígeno quimérico (CARs) anti-CD171. Algunas modalidades se refieren a CARs anti-CD171 que tienen espaciadores polipeptídicos extracelulares largos. Algunas modalidades se refieren a células que contienen tales CARs anti-CD171 que tienen un aumento de persistencia y actividad a una dosis más baja en un sujeto en comparación con células que contienen CARs anti-CD171 que comprenden espaciadores polipeptídicos más cortos.
MX2022015326A 2020-06-08 2021-06-07 Receptores de antigeno quimerico anti-cd171. MX2022015326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063036021P 2020-06-08 2020-06-08
PCT/US2021/036171 WO2021252358A1 (en) 2020-06-08 2021-06-07 Anti-cd171 chimeric antigen receptors

Publications (1)

Publication Number Publication Date
MX2022015326A true MX2022015326A (es) 2023-02-22

Family

ID=78845897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015326A MX2022015326A (es) 2020-06-08 2021-06-07 Receptores de antigeno quimerico anti-cd171.

Country Status (11)

Country Link
US (1) US20230212257A1 (es)
EP (1) EP4161537A1 (es)
JP (1) JP2023529443A (es)
KR (1) KR20230021022A (es)
CN (1) CN115803038A (es)
AU (1) AU2021288464A1 (es)
BR (1) BR112022024941A2 (es)
CA (1) CA3186029A1 (es)
IL (1) IL298779A (es)
MX (1) MX2022015326A (es)
WO (1) WO2021252358A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10137170B2 (en) * 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
CA2931979A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding properties
EP3551197B1 (en) * 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
AU2019319674A1 (en) * 2018-08-06 2021-03-11 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions for stimulation of chimeric antigen receptor T cells with hapten labelled cells

Also Published As

Publication number Publication date
EP4161537A1 (en) 2023-04-12
US20230212257A1 (en) 2023-07-06
AU2021288464A1 (en) 2023-01-19
IL298779A (en) 2023-02-01
CA3186029A1 (en) 2021-12-16
JP2023529443A (ja) 2023-07-10
WO2021252358A1 (en) 2021-12-16
CN115803038A (zh) 2023-03-14
BR112022024941A2 (pt) 2022-12-27
KR20230021022A (ko) 2023-02-13

Similar Documents

Publication Publication Date Title
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
MX2022006365A (es) Receptores de antigeno quimerico cd19 y cd22 y usos de los mismos.
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
ZA202005556B (en) Cartyrin compositions and methods for use
MX2022015062A (es) Nuevas construcciones para receptores de antígenos quiméricos.
PH12020500677A1 (en) Neoantigens and uses thereof
MX2022012082A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
MX2015014017A (es) Variante de la region fc.
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
EA202091982A1 (ru) Химерный антигенный рецептор к рецептору il-13 альфа 2 (il13r2) для опухолеспецифической т-клеточной иммунотерапии
MX2021013355A (es) Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas.
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
NZ702108A (en) Enhanced affinity t cell receptors and methods for making the same
RS54549B1 (en) HUMAN SOFTENING CELLS AND THEIR APPLICATIONS
MX2022008582A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
EP4219560A3 (en) Integrin alpha v beta 8 neutralizing antibody
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
WO2019067951A3 (en) Cd1d and tcr-nkt cells
MX2021010443A (es) Receptores de citocinas quimericos constitutivamente activos.
MX2022007107A (es) Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
MX2022015888A (es) Transfección de ácido ribonucleico mensajero (arnm) de células inmunitarias.
MX2022015326A (es) Receptores de antigeno quimerico anti-cd171.
MX2021011887A (es) Receptores de antigeno quimerico humanizados anti-claudin 18.2 y usos de los mismos.